Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 0%
Hold 82%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is supported by a best-in-class protein reagents franchise and a diagnostics/genomics portfolio that benefits from durable demand in pharma, biotech, academic, and diagnostic markets, with ~20% of sales tied to private/SMID biotech and ~15% exposure to cell therapy after Wilson Wolf. The company also appears well positioned for a funding recovery, as biotech VC, IPO, and secondary activity more than tripled year-to-date year over year through April, which should eventually support demand for its consumables and instruments. Fundamentally, self-help actions such as divesting Exosome Diagnostics and consolidating brands from 10 to 3 should aid margins, while the planned Wilson Wolf acquisition adds growth, high EBITDA margins, and a strategic fit in cell therapy manufacturing.

Bears say

Bio-Techne is facing a negative setup because its core life-science tools markets have still not normalized, and the company has already suffered years of false starts in demand recovery. Its protein sciences business, which drives about 75% of revenue, is exposed to wet-lab research demand that could be structurally pressured if software and AI reduce experiment volume, while diagnostics and genomics also face execution and adoption risk. Competitive pressure is intensifying as key rivals like PeproTech, Abcam, and BioLegend have been acquired by larger players, and with cell therapy tied to roughly 15% of sales, any disappointment there could amplify multiple compression and share loss concerns.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 0% recommend Buy, 82% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Oct 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.